NEW YORK, February 25, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports
highlighting CombiMatrix Corporation (NASDAQ: CBMX), Cepheid
(NASDAQ: CPHD), PerkinElmer, Inc. (NYSE: PKI), Life Technologies
Corp. (NASDAQ: LIFE) and Laboratory Corp. of America Holdings
(NYSE: LH). Today's readers may access these reports free of charge
- including full price targets, industry analysis and analyst
ratings - via the links below.
CombiMatrix Corporation Research
Report
Shares for molecular diagnostics company CombiMatrix surged by
136 percent on the anticipation that it will report impressive
fourth quarter results on February 27,
2013. One of the reasons to be excited for the company's
report is its recent statement regarding significant growth in its
prenatal testing segment. A preliminary growth rate of 172 percent
was recorded for the quarter, as well as a preliminary growth rate
of 171 percent for the full year. This growth was driven by the
company's shift in focus to prenatal molecular diagnostics markets,
where chromosomal microarray analysis (CMA) is quickly becoming a
standard of care. With solid growth in the company's prenatal test
volumes, this anticipation reflected by the company's rise in share
price is well merited. The Full Research Report on CombiMatrix
Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/4e57_CBMX]
--
Cepheid Research Report
Cepheid is collaborating with Knight Cancer Institute at Oregon
Health & Science University (OHSU) to come up with a menu of
advanced molecular diagnostics to be performed on the GeneXpert
system. Together, they aim to develop clinical oncology tests,
mainly for breast and prostate cancer, the two most common cancers
in the US. Many believe that Cepheid's expansion to the oncology
arena will drive the company's growth, given its fast growing
market. The company also plans to triple its production capacity in
2013. Cepheid now has a broad and expanding menu of tests that run
on its GeneXpert systems, including infectious disease, healthcare
associated infections (HAI), women's health, genetics and oncology.
The Full Research Report on Cepheid - including full detailed
breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/cd20_CPHD]
--
PerkinElmer, Inc. Research Report
PerkinElmer recently announced revenue growth of 6 percent in
the fourth quarter of 2012. PerkinElmer CEO Robert Friel comments that he is pleased with
the company's strong finish, capping a solid year of revenue growth
and adjusted operating margin expansion. As an established market
leader in the genetic screening segment, analysts expect the
company to continue its strong performance and many commend the
company's increased productivity and improved product mix. In the
coming year, Friel comments that the company expects to continue
making balanced growth and productivity investments, fostering
growth and profitability for shareholders while addressing critical
health and environment needs. With a competitive pipeline and an
innovative staff, many are optimistic about PerkinElmer's
prospects. The Full Research Report on PerkinElmer, Inc. -
including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/f1d2_PKI]
--
Life Technologies Corp. Research
Report
Life Technologies recently announced the purchase of six Ion
Torrent sequencers for its new Center for Personalized Medicine
(CPM) at Roswell Park Cancer Institute (RPCI). Life Technologies
President and COO Mark Stevenson
notes that over 1000 organizations have adopted Ion Torrent
technology in the past couple of years, giving the company more
than 60 percent of the desktop sequencer market. These products
will give researchers a simple workflow from discovery to
validation. Life Technologies' recent purchase further strengthens
its position in the Ion Torrent technology market, and analysts
note that this is likely to drive the company forward, given the
huge demand for Ion Torrent technology. The company's double-digit
growth is also encouraging, along with its solid margins and solid
cash flow. The Full Research Report on Life Technologies Corp. -
including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/cd9d_LIFE]
--
Laboratory Corp. of America Holdings
Research Report
LabCorp recently announced that it is investing $2 million in SynapDx, an early stage laboratory
services company, to further its development of an autism spectrum
disorder test. This investment demonstrates LabCorp's commitment to
the development of new and better approaches to ASD diagnosis.
Recently, Laboratory Corp also reported net earnings of
$120.2 million or $1.26 per share in the fourth quarter of 2012. It
also announced a new share buyback program of 1 billion. In the
coming year, the company expects higher capital expenditure to
increase the volume of tests, boost IT capabilities, improve
efficiency, further R&D investments and implement alternative
delivery models. LabCorp Chief Executive David King says he expects that the health
changes and the MedicAid expansion will ultimately benefit the
company by increasing testing volume, and he expects revenue to
rise 2 to 3 percent in 2013. The Full Research Report on Laboratory
Corp. of America Holdings - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/96dc_LH]
--
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity...
only to realize that the ship has long sailed? You need a strong,
informative community in your arsenal. Join the group that has been
consistently identifying momentous situations as they develop -
long before they become the next top news on major financial
networks.
Contact: Patricia Byers
Email: press@investors-alliance.com
Main: +1-480-745-7826
SOURCE Investors-Alliance